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Abstract
Objective: Colorectal cancer incidence is greater among African Americans, compared to whites
in the U.S., and may be due in part to differences in diet, genetic variation at metabolic loci, and/or
the joint effect of diet and genetic susceptibility. We examined whether our previously reported
associations between meat-derived heterocyclic amine (HCA) intake and colon cancer were modified
by N-acetyltransferase 1 (NAT1) or 2 (NAT2) genotypes and whether there were differences by race.
Methods: In a population-based, case-control study of colon cancer, exposure to HCAs was
assessed using a food-frequency questionnaire with a meat-cooking and doneness module, among
African Americans (217 cases and 315 controls) and whites (290 cases and 534 controls).
Results: There was no association with NAT1*10 versus NAT1-non*10 genotypes for colon
cancer. Among whites, there was a positive association for NAT2-“rapid/intermediate” genotype
[odds ratio (OR)= 1.4; 95% confidence interval (CI)=1.0, 1.8], compared to the NAT2-“slow” that
was not observed among African Americans. Colon cancer associations with HCA intake were
modified by NAT1, but not NAT2, regardless of race. However, the “at-risk” NAT1 genotype
differed by race. For example, among African Americans, the positive association with 2-amino-1-
methyl-6-phenyl-imidazo[4,5-b]pyridine (PhIP) was confined to those with NAT1*10 genotype
(OR=1.8; 95% CI=1.0, 3.3; P for interaction=0.02, comparing highest to lowest intake), but among
whites, an association with 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) was confined
to those with NAT1-non*10 genotype (OR=1.9; 95% CI=1.1, 3.1; P for interaction=0.03).
Conclusions: Our data indicate modification by NAT1 for HCA and colon cancer associations,
regardless of race. Although the at-risk NAT1 genotype differs by race, the magnitude of the
individual HCA-related associations in both race groups are similar. Therefore, our data do not
support the hypothesis that NAT1 by HCA interactions contribute to differences in colorectal cancer
incidence between African Americans and whites.
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1. Introduction
Colorectal cancer incidence rates have been declining in the U.S., with the steepest decline
since 1990, especially among non-Hispanic whites [1]. Incidence rates (100,000/year) between
2000 and 2004 were higher among African-American males (72.6) and females (55.0),
compared to whites males (60.4) and females (44.0) [2]. Contributing factors to the higher rates
of colorectal cancer among African Americans may include dietary intake [3] and/or eating
behavior [4], genetic variation at metabolic loci [5] and/or joint effects of both dietary factors
and genetic susceptibility [6].
Heterocyclic amines (HCAs) are mutagens and animal carcinogens that are formed when meat
is cooked at high temperatures by methods such as pan frying until it is well-done or has a
charred appearance [7]. Consumption of pan-fried, well-done meat is a surrogate for HCA and
PAH exposure [8], and may be positively associated with colon cancer [9]. Differences in meat
intake patterns by doneness and cooking method have been observed among a population-
based control sample of African Americans and whites in North Carolina, U.S. For example,
among African-American controls, greater intake was observed for pan-fried red meat, well/
very well-done red meat, white meat and pan-fried chicken intake, and the HCAs, 2-amino-3,8-
dimethylimidazo[4,5-f]quinoxaline (MeIQx), and 2-amino-3,4,8-trimethylimidazo[4,5-f]
quinoxaline (DiMeIQx), compared to white controls. In contrast, greater grilled/barbecued red
meat intake was observed among white controls, compared to African-American controls
[10].
HCAs require activation in order to exhibit carcinogenic potential [11]. The initial N-
hydroxylation step occurs in the liver, and is catalyzed by cytochrome p4501A2 (CYP1A2)
[12]. The resulting N-hydroxy HCA derivatives are thought to be stable enough to circulate to
the colon [13,14] where they are activated by N-acetyltransferase 1 (NAT1) and 2 (NAT2)
through O-acetylation leading to the formation of highly reactive N-acetoxy esters [15]. These
compounds undergo spontaneous hydrolysis to form arylnitrenium ions; which have the
potential to covalently bond with DNA to form adducts and thereby increase risk of
mutagenesis and possibly colon cancer [16,17]. NAT1 and NAT2 expression in hepatic, as
well as extrahepatic human tissues has been well documented, with recent mRNA localization
to the surface epithelial cells of the colon and of the crypts of Lieberkuhn [18].
Interindividual differences in the acetylation or metabolic activation of HCAs have been
reported [19]. In addition, NAT1 and NAT2 genotype frequencies vary by race [19,20],
suggesting that racial differences in genetic susceptibility to HCAs may contribute to
differences in colorectal cancer risk. Although several epidemiologic studies have evaluated
whether genetic susceptibility at the NAT loci modify the association between surrogates of
HCA exposure (e.g. meat doneness or cooking method) on risk of colon cancer [21-24], few
data are available that measure individual HCA compounds in a multiethnic population-based
sample. We investigated whether our previously reported findings [10] were modified by
NAT1 or NAT2 genotype, and whether there were differences by race.
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2. Materials and methods
2.1. Study population
Cases and controls of the North Carolina Colon Cancer Study were selected from 33 counties
in North Carolina, U.S., and frequency matched to cases by race (African American, white),
age (<65, ≥65 years), and sex [25]. Details of the study design have been previously described
[10]. In brief, cases were selected through a rapid ascertainment system [26] established in
conjunction with the North Carolina Central Cancer Registry. Cases were eligible if they were
between 40 and 84 years of age at first primary diagnosis of invasive adenocarcinoma of the
colon and diagnosed between 10/01/96 and 09/30/00. Controls were randomly selected from
North Carolina Division of Motor Vehicle lists if they were under 65 years of age, or from the
Center for Medicare and Medicaid Services list if they were 65 years or older. Of those who
were eligible, 84% of cases and 62% of controls were interviewed. The study was approved
by the Institutional Review Board at the University of North Carolina School of Medicine and
by equivalent committees at the collaborating hospitals.
In this study population, African American controls were younger, less educated, and although
more likely to be never smokers, were also more likely to be long-term current smokers,
compared to white controls. Statistically significant case-control differences were not observed
for demographic or smoking characteristics, regardless of race, with the exception of age
among African Americans [10]. Mean daily energy, total fat, total meat, red meat and the
HCAs, DiMeIQx, MeIQx, and 2-amino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine (PhIP)
were greater among cases, compared to controls, regardless of race [10]. Dietary fiber was
inversely associated with colorectal cancer [3], while calcium was only inversely associated
among whites [27]. Although folate intake was not associated with colorectal cancer in this
population [27], an approximate two-fold increase in risk was reported for those with low folate
and the wild-type methylenetetrahydrofolate reductase genotype, regardless of race [28].
2.2. Exposure assessment
Questionnaires were administered in-person in the participants' homes, by specially trained
registered nurses. Information was collected on lifestyle factors such as physical activity and
tobacco use, as well as medical, family, and work histories, and use of over-the-counter
medications. A 150-item food frequency questionnaire was used to measure usual dietary
intake over the year prior to diagnosis for cases, or year prior to date of selection for controls
[29]. The questionnaire was modified to assess individual exposure to dietary carcinogens
based on a meat-cooking and doneness module developed by Sinha, et al. [30]. Details
regarding the collection of dietary history and specifically HCA and PAH exposure have been
previously documented [10]. In brief, frequency, cooking method, and level of doneness of
meat were used to estimate values of three HCAs (MeIQx, PhIP and DiMeIQx) using an
exposure-index that has been previously described in detail [30,31].
2.3. Genotyping
Of the individuals with completed questionnaire data, 88% (93% of cases, and 85% of controls)
also agreed to provide a blood sample for DNA analyses. We were able to successfully amplify
DNA for NAT genotype from 93% of the collected blood samples, leaving 532 African
Americans (217 cases and 315 controls), and 824 whites (290 cases and 534 controls) available
for analysis. As previously reported [32], cases and controls who did not provide blood samples
were more likely to be female (P < 0.01) and white (P < 0.01). There were no other significant
differences, for example, by age, education level, income, family history of colorectal cancer,
smoking status, or total meat intake [10,32].
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Genomic DNA was extracted from whole blood specimens using the PureGene® DNA
isolation kit (Gentra Systems, Inc., Minneapolis, MN). We identified four NAT1 alleles (*3,
*4, *10, *11) and five NAT2 alleles (*4, *5, *6, *7, *14), as defined by Vatsis et al. [33]. Two
assays were used for NAT1 genotyping. The first was the restriction fragment length
polymorphism (RFLP)-polymerase chain reaction (PCR) assay [34]. The second assay was an
allele specific (AS)-PCR, which was used to distinguish between the NAT1*10 and NAT1*3
alleles [34]. Optimal PCR conditions were slightly different from the published protocol. For
the RFLP assay, the PCR cycles were as follows: denaturation at 94°C for 90 seconds,
replication at 94°C for 10 seconds, 56°C for 30 seconds and 72°C for 45 seconds for 35 cycles,
and elongation at 72°C for 4 minutes. For the AS assay, the PCR cycles were as follows:
denaturation at 94°C for 3 minutes, replication at 94°C for 10 seconds, 53°C for 30 seconds
and 72°C for 45 seconds for 30 cycles, and elongation at 72°C for 4 minutes. NAT2 genotyping
was determined by RFLP-PCR methods, as previously described [35]. Optimized PCR cycles
were as follows: denaturation at 94°C for 5 minutes, replication at 94°C for 30 seconds, 50°C
for 30 seconds and 72°C for 90 seconds for 30 cycles, and elongation stage of 72°C for 4
minutes.
For quality control purposes, a 10% random sample of individuals were repeated for NAT1
and NAT2 genotyping to verify initial results. In addition, all assay results were confirmed by
a second independent reader. Genomic DNA extracted from lymphoblastoid cell lines (Corriell
Institute, Camden, NJ) were used as positive controls for each genotype and were included in
every experiment.
2.4. Statistical analysis
NAT1 and NAT2 allele and genotype frequencies were calculated among African-Americans
and whites, cases and controls separately. Individuals were categorized as “NAT1*10” if an
individual had at least one *10 allele, and “NAT1-non*10” if they had none, based on functional
[17] and human studies [36]. Individuals were categorized as “NAT2-rapid” if they were
homozygous for the wild-type *4 allele, “NAT2-intermediate” if they were heterozygous for
the *4 allele, and “NAT2-slow” if they had any other combination of alleles. Observed NAT1
and NAT2 genotype frequencies among controls were compared to expected genotype
frequencies, calculated on the basis of observed allele frequencies under the assumption of
Hardy-Weinberg equilibrium (HWE) [37]. The Pearson chi-square statistic [with degrees of
freedom (df) = number of alleles −1] was used to test whether the expected number of
individuals was significantly different from the observed number of individuals with each
genotype, stratified by race.
All meat (by type, cooking method, doneness preference) and HCA (MeIQx, DiMeIQx, PhIP)
variables were derived from food frequency questionnaire responses. The HCA variables were
derived by multiplying grams of meat intake (stratified by type, doneness and method) by the
compound concentration (ng/day) measured in that meat type [10]. The meat and HCA
variables were categorized into tertiles, based on the distributions among controls. If a
continuous variable had more than 33.3 percent zero values, then quantiles were created by
including all zero values in the reference group and dichotomizing the remaining values (e.g.
>, ≤median value).
For continuous covariates, tertile cutpoints were determined based on the distributions among
all controls. These covariates included: fruits, vegetables, dietary fiber, total fat, dietary folate,
and total energy intake, physical activity, height, weight, and body mass index (kg/m2). Fat
intake was adjusted for total caloric intake using the residual method [38].
Adjusted odds ratios (ORs) and 95 percent confidence intervals (CIs) for colon cancer were
calculated from unconditional logistic regression models [39]. PROC LOGISTIC of the
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software package SAS (version 9.1; SAS Institute, Cary, NC) was used with the option in the
MODEL statement to incorporate offsets, which takes into account the selection probabilities
by age, race, and sex [25]. Multivariable gene effects models included the following variables
to adjust for potential confounding: five-year age groups (≤45, 46-50,…, ≥76 years) and sex.
Multivariable main effects models included the previously mentioned variables for age and
sex, in addition to race (African American, white), dietary fiber, total fat, and total energy
intake, because they were either related both to colon cancer and meat-related variables, a
greater than 10% change in beta estimates was observed for the main effect variable between
unadjusted and adjusted models, or because there was compelling evidence from the literature
for possible confounding. Covariates that were assessed, but did not fulfill the criteria
mentioned above for confounding were mean daily folate intake (>276.6, ≤276.6 μg), smoking
(never, former, current; never, formerly smoked <35 years, formerly smoked ≥35 years,
currently smoke for <35 years, currently smoke for ≥35 years ), mean BMI (>28.5, ≤28.5 kg/
m2), and alcohol intake in past year (ever, never beer, wine or liquor).
Statistical interaction between NAT genotypes and meat-related intake on risk of colon cancer
was evaluated based on deviation from the multiplicative model. Interaction variables were
created for meat-related variables and NAT genotype (e.g. NAT1non-*10, *10 and NAT2-
slow, -rapid/intermediate). Then, the fitness of the interaction term in the model was evaluated
using the likelihood ratio test. Likelihood ratio tests were considered statistically significant at
an alpha level of 0.10 to account for the low power of the test (p. 213-214 in [40]).
3. Results
NAT1 and NAT2 allele and genotype frequencies are presented in Table 1. Genotype
frequencies among controls were in HWE for NAT1 (P = 0.98 among African Americans, P
= 0.65 among whites, with df = 3), and for NAT2 (P = 0.55 among African Americans, P =
0.80 among whites, with df = 4). Among controls, we observed higher frequencies of the
NAT1*10, NAT2-rapid, and NAT2-intermediate genotypes among African Americans, than
among whites. There was no association with colon cancer for NAT1*10 versus NAT1-non*10
genotypes among African Americans or whites (Table 1). Among whites, there was a modest
positive association for NAT2-intermediate genotype [odds ratio (OR)= 1.4; 95% confidence
interval (CI)=1.0, 1.8], compared to the NAT2-slow genotype that was slightly attenuated when
combined with the NAT2-rapid genotype. There was no association for NAT2-intermediate
or combined rapid/intermediate genotypes among African Americans.
Stratified analyses by NAT1 and NAT2 genotype are presented for meat intake, and meat-
derived HCA exposure in relation to colon cancer, separately for African Americans (Table 2)
and whites (Table 3). Among African Americans, statistically significant positive associations
were observed with pan-fried chicken and DiMeIQx, comparing highest to lowest intake, and
with PhIP for mid-level intake (Table 2). These associations were confined to those with
NAT1*10 genotype, and statistical interaction was present at the P<0.10 level. In contrast,
interaction was not observed by NAT2 genotype (Table 2).
Statistically significant positive associations for colon cancer among whites were observed
with well-done red meat, pan-fried red meat, and MeIQx (Table 3). These associations were
confined to those with NAT1-non*10 genotype, in contrast to our findings among African
Americans. Statistical interaction was observed with NAT1 for well-done red meat and MeIQx
at the P<0.01 level. Statistical interaction was not observed between NAT2 genotype and meat
intake or meat-derived HCA intake, except for a borderline statistically significant interaction
for PhIP (Table 3).
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We examined possible interaction between NAT1 and NAT2 genotypes. NAT1 by NAT2
interactions were not observed for colon cancer overall (P for interaction=0.35), or among
whites (P for interaction=0.37). However, interaction was observed among African Americans
(P for interaction=0.06), where a positive association was present among those with NAT1*10
and NAT2-rapid/intermediate genotypes (OR=1.8; 95% CI: 0.9, 3.6), compared to those with
NAT1-non*10 and NAT2-slow genotypes.
4. Discussion
Racial disparities for colon cancer cannot be explained solely by socioeconomic, behavior,
environmental, lifestyle factors, or genetic factors, rather etiologic explanations for these
disparities may include interactions between all of these factors [41]. Using data from a
population-based case-control study, we observed statistically significant interaction between
meat-derived HCA intake and NAT1 genotype, regardless of race. In addition, our data suggest
that NAT1 acetylation of HCAs differs by race, where PhIP increased risk of colon cancer
among African Americans with “fast” acetylation, and MeIQx increased risk among whites
with “slow” acetylation.
Although genetic variation is greater within race/ethnic groups than between, individual single
nucleotide polymorphisms may occur uniquely within specific race/ethnic populations
resulting in allele frequencies that differ between race/ethnic populations and could account
for racial differences in disease susceptibility [42]. To test this hypothesis we measured NAT1
and NAT2 polymorphisms in a population-based sample of African Americans and whites.
We observed a greater frequency of the NAT1*10 and NAT2-rapid/intermediate genotypes
among African-American controls, than among white controls. NAT genotype frequencies
observed in our study population were similar to other case-control studies in the U.S. [43,
44]. Also similar to our findings, in a study of black South Africans, a greater frequency of
NAT2 high activity alleles, compared to whites. Black South Africans have among the lowest
incidence of colon cancer in the world [45], suggesting that the magnitude of association
between NAT2 rapid genotypes and colon cancer may be lower in populations of African versus
European decent. In support of this hypothesis, we observed a weak positive association for
colon cancer with the NAT2-rapid/intermediate genotype versus NAT2-slow, among whites
but not African Americans. In addition no association was observed for NAT1*10, regardless
of race. Our findings among whites were consistent with previous epidemiologic studies that
reported null to weak positive associations for NAT1*10 versus NAT1-non*10, and NAT2-
rapid/intermediate versus NAT2-slow and colon cancer [19,46,47], with some exceptions from
small studies [34,48].
We observed that NAT1 genotype differentially modified the association between dietary
sources of HCA exposure and colon cancer by race, where positive associations were present
among African Americans with the NAT1*10 genotype, and among whites with the NAT1-
non*10 genotype. Although NAT1 polymorphisms contribute to differential N- and O-
acetylation of HCAs [15] and NAT1 activity is greater than NAT2 in the colon [49], few
epidemiologic studies have evaluated NAT1 as a potential modifier of meat and colorectal
cancer associations [50,51]. From a case-control study in Germany, Lilla, et al. reported
stronger positive associations with frequency of red meat consumption among NAT1*10 than
among NAT1-non*10, but interaction was not statistically significant [50]. In a small (N=102
colorectal cases) case-control study, interaction was not observed between red meat and NAT1
genotype, but this may be due to inadequate power [51].
There is epidemiologic evidence for differential effects of acetylation by race. For example,
Probst, et al., reported an inverse association between NAT2 “rapid” genotypes and colorectal
adenomas among African Americans, but an increased risk among whites [52]. Mechanistic
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explanations for differences by race include the differential effect of individual NAT alleles
on HCA acetylation [53]. Our data support this explanation, since we observed differences in
NAT allele frequencies by race. Another mechanistic explanation is that genetic variation by
race exists in other genes that are relevant for HCA metabolism, such as GSTs [54] and
CYP1A2 [12] that are upstream from NAT. Epidemiologic support for this explanation has
been observed where increased risk with well-done red meat only among those with rapid
CYP1A2 and NAT2 in a case-control study of colorectal cancer [55].
Another explanation for our finding includes the effect of unmeasured heterogeneity in other
xenobiotic metabolism genes and/or other environmental factors that may be related to
differences in cancer risk between race/ethnic groups [56]. For example, functional data
suggest that there was differential mutagenic potential for PhIP depending on genetic
variability [57]. One likely suspect is differential glucuronidation of the PhIP intermediate,
where greater activity makes the intermediate unavailable for further activation and eventually
DNA damage [58]. We have previously reported interaction between UDP-
glucuronosyltransferase (UGT) 1A7 and DiMeIQx, although differences by race were not
observed [32].
Our findings of no modification by NAT2 genotype for HCA-colon cancer associations
supports findings from a recent computational study in which observed differences in
mutagenic activity between PhIP and MeIQx intermediates were not related to acetylation with
NAT2 [59]. There have been several epidemiologic studies that have investigated meat intake
and modification by NAT2 genotype for colorectal cancer [44,50,60,61]. However, few studies
have incorporated information on meat cooking method and/or doneness level [21-24,55,62].
Most relevant is that our findings support those of Le Marchand, et al., where no difference
was reported for well-done red meat and colon cancer by NAT2 genotype, because this
population-based, case-control study used similar methods of HCA estimation to our study
[55].
A strength of our study, and a possible reason for previous inconsistent findings of meat-NAT
genotype interactions for colorectal cancer, is the use of rigorous methods to estimate dietary
HCAs [63]. High-quality exposure assessment is particularly important in estimating
interaction with genetic polymorphisms, such as NAT1 and NAT2. By definition they have
low-penetrance and are common in the population, so the association with disease is driven by
the exposure and not by the presence of polymorphisms [64]. However, poor exposure
assessment does not automatically result in biased gene-environment interactions [65].
Misclassification of gene effects may be a source of bias in these data, because genotype data
was used to make assumptions about metabolic activity. Previously, epidemiologic studies
have categorized NAT1 genotypes based on the presence of the *10 allele, because it contains
a DNA sequence variant at the polyadenylation site which increases mRNA stability and
possibly metabolic activity [36,66]. However, this categorization for NAT1 may no longer be
appropriate [67]. One reason is that a novel NAT1 allele (NAT1*14A) was identified, and
determined to be associated with a 15-20 fold reduction in affinity for p-aminosalicylic, a
NAT1-selective substrate [68], whereas NAT1*10 was not [69,70]. The RFLP PCR-based
genotyping methods used in this study, can not be used to distinguish between the NAT1*10
and NAT1*14A alleles. It has been estimated that using the RFLP genotyping methods
misclassifies about 3% of the NAT1*14 alleles as NAT1*10 [71], which would result in a bias
of the observed odds ratio toward the null, given that NAT1*10 genotype is not associated
with diet among controls in these data (data not shown).
Incomplete NAT2 genotype-phenotype correlation may be another source of bias in our study.
We examined three NAT2 SNPs, and although strong evidence exists for their correlation with
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acetylation phenotype [72,73], we have misclassified some rapid acetylators as “slow” and
visa versa. An analysis of the potential bias introduced in measuring three versus eleven NAT2
SNPs concluded that minimal misclassification and only slight biases in interaction estimates
would result [74].
Our data indicate modification by NAT1 for HCA and colon cancer associations, regardless
of race. Although the at-risk NAT1 genotype differs by race, the magnitude of the individual
HCA-related associations in both race groups are similar. Therefore, our data do not support
the hypothesis that NAT1 by HCA interactions contribute to differences in colorectal cancer
incidence between African Americans and whites.
Reducing risk of colorectal cancer can be furthered with research on the genetic susceptibility
of modifiable exposures, including dietary factors [75]. For example, chemopreventive
strategies are currently being investigated to reduce the effects of HCA exposure that activate
detoxification pathways in general [76], or specifically by activation CYP1A2 [77] and GSTs
[78]. Reducing red meat intake, particularly pan fried meat, and increasing intake of foods
known enhance detoxification enzymes remain to be important for reducing risk of colon
cancer among both African Americans and whites.
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Table 2
Odds ratios with meat-related intake, overall and stratified by NAT1 and NAT2 genotype, for colon cancer,
among African Americans
Daily well/very well-done red meat intake (tertile median, g)
4.2 21.4 50.1
OR (95% CI) 1.0 (ref)a 1.0 (0.6, 1.7) 1.7 (0.9, 3.0)
Cases/controls 43/80 60/112 114/123
NAT1
 Non*10 OR (95% CI) 1.0 (ref)a 0.6 (0.2, 1.8) 1.0 (0.3, 3.2)
Cases/controlsb 15/15 18/29 32/39
 *10 OR (95% CI) 1.0 (ref) 1.1 (0.6, 2.1) 2.2 (1.0, 4.7)
Cases/controls 26/61 38/77 79/78
p-value = 0.08e
NAT2
 Slow OR (95% CI) 1.0 (ref)a 1.0 (0.4, 2.7) 1.2 (0.5, 3.3)
Cases/controlsc 15/29 25/37 43/54
 Rapid/
intermediate OR (95% CI) 1.0 (ref) 0.9 (0.5, 1.9) 2.0 (0.9, 4.3)
Cases/controls 28/49 34/72 70/66
p-value = 0.28e
Daily pan fried red meat intake (tertile median, g)
0.0 9.0 30.0
OR (95% CI) 1.0 (ref)a 1.0 (0.6, 1.7) 1.4 (0.8, 2.4)
Cases/controls 43/78 57/109 117/128
NAT1
 Non*10 OR (95% CI) 1.0 (ref)a 0.5 (0.2, 1.6) 0.9 (0.3, 2.7)
Cases/controlsb 14/15 18/32 33/36
 *10 OR (95% CI) 1.0 (ref) 1.3 (0.7, 2.4) 1.5 (0.8, 3.0)
Cases/controls 25/57 38/72 80/87
p-value = 0.23e
NAT2
 Slow OR (95% CI) 1.0 (ref)a 1.1 (0.4, 2.6) 0.8 (0.4, 2.6)
Cases/controlsc 15/24 25/43 43/53
 Rapid/
intermediate OR (95% CI) 1.0 (ref) 1.2 (0.6, 2.3) 1.9 (0.9, 3.9)
Cases/controls 27/53 31/62 74/72
p-value = 0.28e
Daily pan fried chicken intake (tertile median, g)
0.0 4.2 14.6
OR (95% CI) 1.0 (ref)a 1.2 (0.7, 2.0) 1.8 (1.2, 2.7)
Cases/controls 97/179 40/57 80/79
NAT1
 Non*10 OR (95% CI) 1.0 (ref)a 1.0 (0.4, 3.0) 1.3 (0.5, 2.9)
Cases/controlsb 33/42 10/14 22/27
 *10 OR (95% CI) 1.0 (ref) 1.4 (0.7, 2.6) 2.6 (1.5, 4.5)
Cases/controls 59/129 28/41 56/46
p-value = 0.07e
NAT2
 Slow OR (95% CI) 1.0 (ref)a 1.3 (0.6, 3.0) 2.7 (1.3, 5.8)
Cases/controlsc 33/69 18/26 32/25
 Rapid/
intermediate OR (95% CI) 1.0 (ref) 1.1 (0.5, 2.1) 1.4 (0.8, 2.4)
Cases/controls 63/104 22/31 47/52
p-value = 0.19e
Daily DiMeIQx intake (tertile median, ng)
0.3 2.2 7.6
OR (95% CI) 1.0 (ref)d 1.8 (1.1, 3.0) 1.7 (1.0, 2.9)
Cases/controls 36/92 80/105 101/118
NAT1
 Non*10 OR (95% CI) 1.0 (ref)d 0.9 (0.4, 2.5) 0.7 (0.3, 2.0)
Cases/controlsb 13/16 28/34 24/33
 *10 OR (95% CI) 1.0 (ref)d 2.3 (1.2, 4.6) 2.3 (1.2, 4.6)
Cases/controls 21/70 48/65 74/81
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 Slow OR (95% CI) 1.0 (ref)d 1.7 (0.7, 4.1) 1.9 (0.8, 4.7)
Cases/controlsc 14/32 29/43 40/45
 Rapid/
intermediate OR (95% CI) 1.0 (ref)
d 1.8 (0.9, 3.5) 1.6 (0.8, 3.2)
Cases/controls 22/56 50/61 60/70
p-value = 0.63e
Daily MeIQx intake (tertile median, ng)
8.0 38.1 90.8
OR (95% CI) 1.0 (ref)d 1.2 (0.7, 2.0) 1.3 (0.8, 2.3)
Cases/controls 41/82 73/116 103/117
NAT1
 Non*10 OR (95% CI) 1.0 (ref)d 0.7 (0.3, 1.8) 0.6 (0.2, 1.7)
Cases/controlsb 15/16 26/34 24/33
 *10 OR (95% CI) 1.0 (ref)d 1.2 (0.6, 2.4) 1.7 (0.8, 3.3)
Cases/controls 24/59 43/78 76/79
p-value = 0.09e
NAT2
 Slow OR (95% CI) 1.0 (ref)d 1.3 (0.5, 3.1) 1.2 (0.5, 3.0)
Cases/controlsb 14/27 29/45 40/48
 Rapid/
intermediate OR (95% CI) 1.0 (ref)
d 1.1 (0.6, 2.0) 1.4 (0.7, 2.9)
Cases/controls 27/52 42/69 63/66
p-value = 0.65e
Daily PhIP intake (tertile median, ng)
3.7 42.4 148.2
OR (95% CI) 1.0 (ref)d 1.8 (1.1, 2.8) 1.3 (0.8, 2.1)
Cases/controls 59/121 73/84 85/110
NAT1
 Non*10 OR (95% CI) 1.0 (ref)d 0.9 (0.4, 2.2) 0.5 (0.2, 1.4)
Cases/controlsb 21/22 22/26 22/35
 *10 OR (95% CI) 1.0 (ref)d 2.4 (1.3, 4.4) 1.8 (1.0, 3.3)
Cases/controls 35/91 49/53 59/72
p-value = 0.02e
NAT2
 Slow OR (95% CI) 1.0 (ref)d 1.0 (0.4, 2.1) 0.9 (0.4, 1.9)
Cases/controlsc 25/37 26/38 32/45
 Rapid/
intermediate OR (95% CI) 1.0 (ref)
d 2.2 (1.2, 4.1) 1.5 (0.8, 2.8)
Cases/controls 34/80 45/45 53/62
p-value = 0.12e
a
Adjusted for age, race, sex, total meat, energy-adjusted fat intake, dietary fiber intake, total energy, and offsets.
b
Missing NAT1 data: N=9 cases and 16 controls.
c
Missing NAT2 data: N=2 cases and 8 controls.
d
Adjusted for age, race, sex, energy-adjusted fat intake, dietary fiber intake, total energy, and offsets.
e
Likelihood ratio test p-value to assess interaction.
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Table 3
Odds ratios with meat-related intake, overall and stratified by NAT1 and NAT2 genotype, for colon cancer,
among whites
Daily well/very well-done red meat intake (tertile median, g)
4.7 21.2 44.8
OR (95% CI) 1.0 (ref)a 1.2 (0.8, 1.8) 1.5 (0.9, 2.3)
Cases/controls 81/192 97/181 112/161
NAT1
 Non*10 OR (95% CI) 1.0 (ref)a 1.2 (0.7, 2.0) 1.9 (1.1, 3.4)
Cases/controlsb 46/123 62/131 78/106
 *10 OR (95% CI) 1.0 (ref)a 1.4 (0.7, 2.8) 0.8 (0.4, 2.0)
Cases/controls 32/64 35/49 29/55
p-value = 0.02e
NAT2
 Slow OR (95% CI) 1.0 (ref)a 1.0 (0.6, 1.9) 1.2 (0.6, 2.3)
Cases/controlsc 43/114 50/104 51/87
 Rapid/
intermediate
OR (95% CI) 1.0 (ref)a 1.2 (0.7, 2.2) 1.6 (0.8, 3.3)
Cases/controls 38/73 46/74 57/71
p-value = 0.46e
Daily pan fried red meat intake (tertile median, g)
0.0 9.0 30.0
OR (95% CI) 1.0 (ref)a 1.4 (0.9, 2.0) 2.0 (1.3, 3.1)
Cases/controls 75/199 92/174 123/161
NAT1
 Non*10 OR (95% CI) 1.0 (ref)a 1.3 (0.8, 2.2) 2.2 (1.3, 3.8)
Cases/controlsb 46/131 59/124 81/105
 *10 OR (95% CI) 1.0 (ref)a 1.6 (0.8, 3.3) 1.5 (0.7, 3.3)
Cases/controls 26/62 33/50 37/56
p-value = 0.13e
NAT2
 Slow OR (95% CI) 1.0 (ref)a 1.2 (0.7, 2.0) 2.0 (1.1, 3.7)
Cases/controlsc 37/113 42/102 65/90
 Rapid/
intermediate
OR (95% CI) 1.0 (ref)a 1.4 (0.8, 2.5) 1.6 (0.8, 3.0)
Cases/controls 38/79 48/69 55/70
p-value = 0.27e
Daily pan fried chicken intake (tertile median, g)
0.0 4.2 10.9
OR (95% CI) 1.0 (ref)a 0.9 (0.6, 1.3) 0.9 (0.5, 1.4)
Cases/controls 208/385 47/85 35/64
NAT1
 Non*10 OR (95% CI) 1.0 (ref)a 0.9 (0.5, 1.5) 0.7 (0.4, 1.3)
Cases/controlsb 136/261 31/58 19/41
 *10 OR (95% CI) 1.0 (ref)a 0.8 (0.4, 1.7) 1.0 (0.5, 2.2)
Cases/controls 69/119 13/26 14/23
p-value = 0.42e
NAT2
 Slow OR (95% CI) 1.0 (ref)a 0.9 (0.5, 1.6) 1.0 (0.5, 1.9)
Cases/controlsc 103/222 22/47 19/36
 Rapid/
intermediate
OR (95% CI) 1.0 (ref)a 0.9 (0.5, 1.7) 0.7 (0.4, 1.4)
Cases/controls 102/154 23/36 16/28
p-value = 0.50e
Daily DiMeIQx intake (tertile median, ng)
0.2 2.4 7.2
OR (95% CI) 1.0 (ref)d 1.1 (0.8, 1.6) 1.2 (0.8, 1.8)
Cases/controls 82/183 99/183 109/168
NAT1
 Non*10 OR (95% CI) 1.0 (ref)d 0.9 (0.6, 1.5) 1.2 (0.7, 1.9)
Cases/controlsb 53/120 61/128 72/112
 *10 OR (95% CI) 1.0 (ref)d 1.6 (0.8, 3.2) 1.0 (0.5, 2.2)
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Daily well/very well-done red meat intake (tertile median, g)
4.7 21.2 44.8
Cases/controls 27/59 37/53 32/56
p-value = 0.09e
NAT2
 Slow OR (95% CI) 1.0 (ref)d 1.0 (0.6, 1.7) 1.1 (0.6, 1.8)
Cases/controlsc 45/109 49/107 50/89
 Rapid/
intermediate
OR (95% CI) 1.0 (ref)d 1.2 (0.7, 2.1) 1.2 (0.6, 2.1)
Cases/controls 37/69 49/72 55/77
p-value = 0.89e
Daily MeIQx intake (tertile median, ng)
9.6 36.3 96.6
OR (95% CI) 1.0 (ref)d 1.2 (0.8, 1.8) 1.4 (0.9, 2.2)
Cases/controls 78/193 98/180 114/161
NAT1
 Non*10 OR (95% CI) 1.0 (ref)d 1.3 (0.8, 2.0) 1.9 (1.1, 3.1)
Cases/controlsb 46/129 65/130 75/101
 *10 OR (95% CI) 1.0 (ref)d 1.3 (0.7, 2.6) 0.8 (0.4, 1.7)
Cases/controls 29/59 33/49 34/60
p-value = 0.03e
NAT2
 Slow OR (95% CI) 1.0 (ref)d 1.3 (0.7, 2.1) 1.5 (0.8, 2.7)
Cases/controlsc 39/117 51/105 54/83
 Rapid/
intermediate
OR (95% CI) 1.0 (ref)d 1.0 (0.6, 1.8) 1.1 (0.6, 2.0)
Cases/controls 39/70 46/72 56/76
p-value = 0.31e
Daily PhIP intake (tertile median, ng)
2.5 45.6 137.3
OR (95% CI) 1.0 (ref)d 0.8 (0.5, 1.2) 1.3 (0.9, 2.0)
Cases/controls 70/151 89/208 131/175
NAT1
 Non*10 OR (95% CI) 1.0 (ref)d 0.8 (0.5, 1.3) 1.4 (0.9, 2.3)
Cases/controlsb 47/106 51/136 88/118
 *10 OR (95% CI) 1.0 (ref)d 1.0 (0.5, 2.1) 1.2 (0.5, 2.5)
Cases/controls 21/42 37/69 38/57
p-value = 0.14e
NAT2
 Slow OR (95% CI) 1.0 (ref)d 0.5 (0.3, 0.9) 1.1 (0.6, 2.0)
Cases/controlsc 41/86 37/122 66/97
 Rapid/
intermediate
OR (95% CI) 1.0 (ref)d 1.1 (0.6, 2.1) 1.5 (0.8, 2.9)
Cases/controls 29/60 50/84 62/74
p-value = 0.08e
a
Adjusted for age, race, sex, total meat, energy-adjusted fat intake, dietary fiber intake, total energy, and offsets.
b
Missing NAT1 data: N=8 cases and 6 controls.
c
Missing NAT2 data: N=5 cases and 11 controls.
d
Adjusted for age, race, sex, energy-adjusted fat intake, dietary fiber intake, total energy, and offsets.
e
Likelihood ratio test p-value to assess interaction.
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